ReviewClinical reviews in allergy & immunology2002
Monitoring inflammation in CF. Cytokines.
Review in Clinical reviews in allergy & immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.Thorax · 2006Trial
- Article
- Cathepsin B, Airway Pathogens, and Inflammation in the Lower Airways of Children With Cystic Fibrosis.Pediatric pulmonology · 2026Article
- Detection and identification of fungi in the lower airway of children with and without cystic fibrosis.Frontiers in microbiology · 2023Article
- Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis.Pediatric pulmonology · 2022Article
- Network Analysis to Identify Multi-Omic Correlations in the Lower Airways of Children With Cystic Fibrosis.Frontiers in cellular and infection microbiology · 2022Article
- Increased Inflammatory Markers Detected in Nasal Lavage Correlate with Paranasal Sinus Abnormalities at MRI in Adolescent Patients with Cystic Fibrosis.Antioxidants (Basel, Switzerland) · 2021Article
- Divergence of bacterial communities in the lower airways of CF patients in early childhood.PloS one · 2021Article
- Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.Cellular & molecular immunology · 2018Review
- Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.Mediators of inflammation · 2015Article
- Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.American journal of respiratory cell and molecular biology · 2011Article
- Article
- HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.Journal of inflammation (London, England) · 2010Article
- The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model.Gene therapy · 2009Article
- The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis.Respiratory research · 2008Article
- Gene therapy for cystic fibrosis.Clinical reviews in allergy & immunology · 2008Review
- Potential role of high-mobility group box 1 in cystic fibrosis airway disease.American journal of respiratory and critical care medicine · 2008Article
- Sputum biomarkers of inflammation in cystic fibrosis lung disease.Proceedings of the American Thoracic Society · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In cystic fibrosis (CF), chronic airway infection and neutrophil-dominated airway inflammation lead to progressive lung disease. Cytokines play an important role in the inflammatory response. Evidence suggests that cytokine production is altered or dysregulated in CF. Moreover, polymorphisms in cytokines may be linked to disease severity by acting as modifier genes. This article reviews the current state of knowledge regarding individual cytokines and CF lung disease, with an eye towards the possibility that cytokines may be used as outcome measures in clinical trials in CF. In addition, cytokines may eventually serve as targets for novel anti-inflammatory therapies in CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.